Transgene Beheer

Beheer criteriumcontroles 2/4

De CEO Transgene is Alessandro Riva, benoemd in Jun2023, heeft een ambtstermijn van 1.42 jaar. De totale jaarlijkse vergoeding van { bedraagt € 510.00K, bestaande uit 68.6% salaris en 31.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.022% van de aandelen van het bedrijf, ter waarde € 22.93K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.7 jaar en 4.8 jaar.

Belangrijke informatie

Alessandro Riva

Algemeen directeur

€510.0k

Totale compensatie

Percentage CEO-salaris	68.6%
Dienstverband CEO	1.4yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Alessandro Riva's beloning veranderd ten opzichte van Transgene's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-€23m
Mar 31 2024	n/a	n/a	-€23m
Dec 31 2023	€510k	€350k	-€22m
Sep 30 2023	n/a	n/a	-€28m
Jun 30 2023	n/a	n/a	-€33m
Mar 31 2023	n/a	n/a	-€33m
Dec 31 2022	€304k	n/a	-€33m

Compensatie versus markt: De totale vergoeding ($USD 534.59K ) Alessandro } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.67K ).

Compensatie versus inkomsten: De vergoeding van Alessandro is gestegen terwijl het bedrijf verliesgevend is.

CEO

Alessandro Riva (63 yo)

1.4yrs

Tenure

€510,000

Compensatie

Dr. Alessandro Riva, M.D., serves as Chairman of the Board and Chief Executive Officer of Transgene SA since June 1, 2023. He serves as Independent Non-Executive Director at BeiGene, Ltd. since February 01...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alessandro Riva	CEO & Chairman of the Board	1.4yrs	€510.00k	0.022% € 22.9k
Lucie Larguier	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Maurizio Ceppi	Vice President & Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
John Felitti	VP, General Counsel & Corporate Secretary	8.7yrs	geen gegevens	geen gegevens
Christelle Schwoerer	Chief Human Resources Officer	less than a year	geen gegevens	geen gegevens
James Wentworth	VP & Chief Business Officer	less than a year	geen gegevens	geen gegevens
Emmanuelle Dochy	VP of Medical Affairs & Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Gaelle Stadtler	VP & Director of Human Resources	no data	geen gegevens	geen gegevens
Kaidre Bendjama	Project Leader of Personalized Cancer Vaccines	no data	geen gegevens	geen gegevens

0.7yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TGNA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.7 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Alessandro Riva	CEO & Chairman of the Board	2.5yrs	€510.00k	0.022% € 22.9k
Benoit Habert	Director	24.8yrs	€34.00k	0.078% € 80.5k
Alain Merieux	Honorary Chairman	4.8yrs	geen gegevens	69.27% € 71.5m
Jean-Luc Belingard	Non-Independent Director	11.4yrs	geen gegevens	geen gegevens
Philippe Archinard	Director	19.9yrs	geen gegevens	0.43% € 441.6k
Jean-Yves Blay	Independent Director	2.5yrs	€21.00k	geen gegevens
John Bell	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Pedro Romero	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Marie-Yvonne Landel-Meunier	Independent Director	7.4yrs	€53.00k	geen gegevens
Carol Stuckley	Independent Director	1.5yrs	geen gegevens	geen gegevens
Maya Said	Independent Director	7.4yrs	€75.00k	geen gegevens
Sandrine Flory	Director	3.8yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TGNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Transgene Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Transgene SA Announces Chief Financial Officer Changes

Transgene SA Appoints Carol Stuckley as Independent Director

Transgene SA Approves Board and Committee Changes

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Recent updates

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023)

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

New major risk - Financial position

Full year 2023 earnings released: €0.22 loss per share (vs €0.33 loss in FY 2022)

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

New major risk - Financial position

New minor risk - Share price stability

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Full year 2022 earnings released: €0.33 loss per share (vs €0.21 loss in FY 2021)

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue misses expectations

New 90-day high: €2.84

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

New 90-day high: €2.69

New 90-day high: €2.60

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.74

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

First half 2020 earnings released: €0.03 loss per share

New 90-day high: €1.57

Transgene SA Announces the Presentation of the Detailed Results from the Phase 1b/2 Trial Combining TG4001, a HPV16-Targeted Therapeutic Vaccine, with Avelumab (BAVENCIO®)

Transgene Announces Detailed Results from the Phase 1B/2 Trial Combining TG4001

Transgene Announces Detailed Results of the Data from the Phase 1b/2 Trial Combining TG4001

Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers

Transgene SA to Report Fiscal Year 2009 Results on 03/22/2010

First half earnings released

New 90-day low - €1.33

A Chinese Investment Fund acquired an unknown minority stake in Shanghai Tasly Pharmaceutical Co., Ltd from Transgene SA (ENXTPA:TNG) for $22.2 million.

Vaxxel SAS acquired DuckCelt®-T17 cell line of Transgene SA (ENXTPA:TNG).

Mediolanum Farmaceutici S.P.A. acquired ElsaLys Biotech SA.

Analyse CEO-vergoeding

CEO

Tenure